Evidence map›Paper›PMID 30914828›Full record

ArticleEuropean journal of human genetics : EJHG2019

Phenotypic spectrum associated with a CRADD founder variant underlying frontotemporal predominant pachygyria in the Finnish population.

Daniel L Polla, Elisa Rahikkala, Michaela K Bode, Tuomo Määttä, Teppo Varilo, Thyrza Loman, Anju K Philips, Mitja Kurki, Aarno Palotie, Jarmo Körkkö and 9 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 5 countries.

Daniel L PollaDepartment of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-5552-3488
Elisa RahikkalaDepartment of Clinical Genetics, PEDEGO Research Unit and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Michaela K BodeDepartment of Diagnostic Radiology, Oulu University Hospital and Medical Research Center Oulu, Oulu, Finland.
Tuomo MäättäDisability Services, Joint Authority for Kainuu, Kainuu, Finland.
Teppo VariloDepartment of Medical Genetics, University of Helsinki, Helsinki, Finland.
Thyrza LomanDepartment of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Anju K PhilipsDepartment of Medical Genetics, University of Helsinki, Helsinki, Finland.
Mitja KurkiPsychiatric & Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
Aarno PalotiePsychiatric & Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
Jarmo KörkköNorthern Ostrobothnia Hospital District, Center for Intellectual Disability Care, 90220, Oulu, Finland.
Päivi VieiraClinic for Children and Adolescents, PEDEGO Research Unit and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Kristiina AvelaDepartment of Clinical Genetics, Helsinki University Hospital, Helsinki, Finland.
Valérie JacqueminMedical Genetics, IRIBHM, Université Libre de Bruxelles, Brussels, Belgium.
Isabelle PirsonMedical Genetics, IRIBHM, Université Libre de Bruxelles, Brussels, Belgium.
Marc AbramowiczMedical Genetics, IRIBHM, Université Libre de Bruxelles, Brussels, Belgium.
Arjan P M de BrouwerDepartment of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Outi KuisminDepartment of Clinical Genetics, PEDEGO Research Unit and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Hans van BokhovenDepartment of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Irma JärveläDepartment of Medical Genetics, University of Helsinki, Helsinki, Finland. irma.jarvela@helsinki.fi.
University of Helsinki · FIOulu University Hospital · FIRadboud University Nijmegen · NLUniversité Libre de Bruxelles · BEBroad Institute · USKajaani University of Applied Sciences · FIMinistry of Education · BRNorthern Ostrobothnia Hospital District · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intellectual disability (ID), megalencephaly, frontal predominant pachygyria, and seizures, previously called "thin" lissencephaly, are reported to be caused by recessive variants in CRADD. Among five families of different ethnicities identified, one homozygous missense variant, c.509G>A p.(Arg170His), was of Finnish ancestry. Here we report on the phenotypic variability associated for this potential CRADD founder variant in 22 Finnish individuals. Exome sequencing was used to identify candidate genes in Finnish patients presenting with ID. Targeted Sanger sequencing and restriction enzyme analysis were applied to screen for the c.509G>A CRADD variant in cohorts from Finland. Detailed phenotyping and genealogical studies were performed. Twenty two patients were identified with the c.509G>A p.(Arg170His) homozygous variant in CRADD. The majority of the ancestors originated from Northeastern Finland indicating a founder effect. The hallmark of the disease is frontotemporal predominant pachygyria with mild cortical thickening. All patients show ID of variable severity. Aggressive behavior was found in nearly half of the patients, EEG abnormalities in five patients and megalencephaly in three patients. This study provides detailed data about the phenotypic spectrum of patients with lissencephaly due to a CRADD variant that affects function. High inter- and intrafamilial phenotypic heterogeneity was identified in patients with pachygyria caused by the homozygous CRADD founder variant. The phenotype variability suggests that additional genetic and/or environmental factors play a role in the clinical presentation. Since frontotemporal pachygyria is the hallmark of the disease, brain imaging studies are essential to support the molecular diagnosis for individuals with ID and a CRADD variant.

Indexed as

Founder EffectMutation, MissenseBrainCRADD Signaling Adaptor ProteinExome SequencingFamily HealthFemaleFinlandGenetic Predisposition to DiseaseGeographyHomozygoteHumansLissencephalyMagnetic Resonance ImagingMalePedigreeCRADD protein, humanCRADD Signaling Adaptor Protein

Identifiers

PMID30914828
PMCPMC6777631
OpenAlexW2925082328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.